Novavax Inc. (NVAX) shares plummeted on Wednesday after the FDA placed a clinical hold on the company’s Investigational New Drug (IND) application for its combined COVID-19/influenza vaccine candidate. The hold was triggered by a single instance of motor neuropathy reported in a participant outside the U.S., raising concerns about the vaccine’s safety.